Concepedia

Roy Krumbholz

RK

Statistics

Publications

7

Citations

363

H-Index

7

Active since

2008

Affiliations

SynZyme Technologies (United States)(Current)

Rutgers, The State University of New Jersey

Gene Therapy Laboratory

Roy Krumbholz is an author at SynZyme Technologies (United States) specializing in molecular oncology, cancer pharmacology, and oncology.

Publications per year

2008–2015

7

Publications

7

SCD1 Inhibition Causes Cancer Cell Death by Depleting Mono-Unsaturated Fatty Acids

Paul Mason, Beirong Liang, Lingyun Li et al. · PLoS ONE · 2012 · 171 citations · Full text

, , +17

Genz-644282, a Novel Non-Camptothecin Topoisomerase I Inhibitor for Cancer Treatment

Leslie Kurtzberg, Stéphanie Roth, Roy Krumbholz et al. · Clinical Cancer Research · 2011 · 50 citations

, , +13

Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors

Leslie Kurtzberg, Traci E. Battle, Cécile Rouleau et al. · Molecular Cancer Therapeutics · 2008 · 37 citations

, , +13

Anti-Endosialin Antibody–Drug Conjugate: Potential in Sarcoma and Other Malignancies

Cécile Rouleau, Diego A. Gianolio, Robert Smale et al. · Molecular Cancer Therapeutics · 2015 · 36 citations

, , +16

Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody–drug conjugates

Diego A. Gianolio, Cécile Rouleau, William E. Bauta et al. · Cancer Chemotherapy and Pharmacology · 2012 · 33 citations

, , +16

1–5 of 7